Advanced search
Publication Cover
The Journal of Maternal-Fetal & Neonatal Medicine Volume 36, 2023 - Issue 1
Submit an article Journal homepage
3,532
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Proteomic profile of extracellular vesicles in maternal plasma of women with fetal death

Dahiana M. Galloa Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USA;d Department of Obstetrics and Gynecology, Universidad Del Valle, Cali, ColombiaView further author information
,
Wendy Fitzgeralde Section on Intercellular Interactions, National Institutes of Health, Bethesda, MD, USAView further author information
,
Roberto Romeroa Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;f Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA;g Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA;h Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA;i Detroit Medical Center, Detroit, MI, USAView further author information
,
Nardhy Gomez-Lopeza Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USA;j Department of Biochemistry, Microbiology and Immunology, Wayne State University School of Medicine, Detroit, Michigan, USAView further author information
,
Dereje W. Gudichaa Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USAView further author information
,
Nándor Gábor Thana Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;k Systems, Biology of Reproduction Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary;l Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary;m Maternity Private Clinic of Obstetrics and Gynecology, Budapest, HungaryView further author information
,
Mariachiara Boscoa Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USAView further author information
,
Tinnakorn Chaiworapongsaa Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USAView further author information
,
Eunjung Junga Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USAView further author information
,
Arun Meyyazhagana Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USAView further author information
,
Manaphat Suksaia Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USAView further author information
,
Francesca Gotscha Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;c Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USAView further author information
,
Offer Ereza Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;n Department of Obstetrics and Gynecology, HaEmek Medical Center, Afula, IsraelORCID Iconhttps://orcid.org/0000-0002-2213-8129View further author information
ORCID Icon,
Adi L. Tarcaa Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Detroit, MI, USA;b Division of Intramural Research, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA;o Department of Computer Science, Wayne State University College of Engineering, Detroit, MI, USAView further author information
&
Leonid Margolise Section on Intercellular Interactions, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
View further author information
 show all
Article: 2177529 | Received 24 Nov 2022, Accepted 30 Jan 2023, Published online: 22 Feb 2023

References

  • MacDorman MF, Gregory EC. Fetal and perinatal mortality: United States, 2013. Natl Vital Stat Rep. 2015;64(8):1–24.
  • Willinger M, Ko CW, Reddy UM. Racial disparities in stillbirth risk across gestation in the United States. Am J Obstet Gynecol. 2009;201(5):469.e1-8–469.e8.
  • Hug L, You D, Blencowe H, et al. Global, regional, and national estimates and trends in stillbirths from 2000 to 2019: a systematic assessment. Lancet. 2021;398(10302):772–785.
  • Silver RM, Varner MW, Reddy U, et al. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol. 2007;196(5):433–444.
  • Pacora P, Romero R, Jaiman S, et al. Mechanisms of death in structurally normal stillbirths. J Perinat Med. 2019;47(2):222–240.
  • Jaiman S, Romero R, Pacora P, Jung E, Bhatti G, Yeo L, et al. Disorders of placental villous maturation in fetal death. J Perinat Med. 2020.
  • Silver RM, Saade GR, Thorsten V, et al. Factor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase mutations and stillbirth: the Stillbirth Collaborative Research Network. Am J Obstet Gynecol. 2016;215(4):468.e1–e17.
  • Takita H, Hasegawa J, Nakamura M, et al. Causes of intrauterine fetal death are changing in recent years. J Perinat Med. 2018;46(1):97–101.
  • Reddy UM, Goldenberg R, Silver R, et al. Stillbirth classification–developing an international consensus for research: executive summary of a National Institute of Child Health and Human Development workshop. Obstet Gynecol. 2009;114(4):901–914.
  • Hoyert DL, Gregory EC. Cause of fetal death: data from the fetal death report, 2014. Natl Vital Stat Rep. 2016;65(7):1–25.
  • Romero R. Prenatal medicine: the child is the father of the man. Prenat Neonat Med. 1996;1:8–11.
  • McPherson EW. 3137 fetuses in 33 years: what we have learned from the Wisconsin stillbirth service program. Am J Med Genet. 2021;185(9):2683–2689.
  • Huang DY, Usher RH, Kramer MS, et al. Determinants of unexplained antepartum fetal deaths. Obstet Gynecol. 2000;95(2):215–221.
  • Frøen JF, Arnestad M, Frey K, et al. Risk factors for sudden intrauterine unexplained death: epidemiologic characteristics of singleton cases in Oslo, Norway, 1986–1995. Am J Obstet Gynecol. 2001;184(4):694–702.
  • Yudkin PL, Wood L, Redman CW. Risk of unexplained stillbirth at different gestational ages. Lancet. 1987;1(8543):1192–1194.
  • Causes of death among stillbirths. Jama. 2011;306:2459–2468.
  • Nappi L, Trezza F, Bufo P, et al. Classification of stillbirths is an ongoing dilemma. J Perinat Med. 2016;44(7):837–843.
  • Smith GC, Fretts RC. Stillbirth. Lancet. 2007;370(9600):1715–1725.
  • Aminu M, Bar-Zeev S, van den Broek N. Cause of and factors associated with stillbirth: a systematic review of classification systems. Acta Obstet Gynecol Scand. 2017;96(5):519–528.
  • Docheva N, Romero R, Chaemsaithong P, et al. The profiles of soluble adhesion molecules in the "great obstetrical syndromes. J Matern Fetal Neonatal Med. 2019;32(13):2113–2136.
  • Chaemsaithong P, Chaiworapongsa T, Romero R, et al. Maternal plasma soluble TRAIL is decreased in preeclampsia. J Matern Fetal Neonatal Med. 2014;27(3):217–227.
  • Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol. 2013;208(4):287.e1–e15.
  • Crispi F, Domínguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol. 2006;195(1):201–207.
  • Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med. 2008;21(1):25–40.
  • Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.
  • Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–683.
  • Gotsch F, Romero R, Friel L, et al. CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med. 2007;20(11):777–792.
  • Staff AC, Braekke K, Johnsen GM, et al. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol. 2007;197(2):176.e1-6–176.e6.
  • Baumann MU, Bersinger NA, Mohaupt MG, et al. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol. 2008;199(3):266.e1-6–266.e6.
  • Chaiworapongsa T, Romero R, Whitten AE, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med. 2016;29(8):1214–1228.
  • Birdir C, Fryze J, Frölich S, et al. Impact of maternal serum levels of visfatin, AFP, PAPP-A, sFlt-1 and PlGF at 11-13 weeks gestation on small for gestational age births. J Matern Fetal Neonatal Med. 2017;30(6):629–634.
  • Chaiworapongsa T, Romero R, Gotsch F, et al. Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. J Matern Fetal Neonatal Med. 2010;23(2):167–178.
  • Soto E, Romero R, Vaisbuch E, et al. Fragment bb: evidence for activation of the alternative pathway of the complement system in pregnant women with acute pyelonephritis. J Matern Fetal Neonatal Med. 2010;23(10):1085–1090.
  • Assi F, Fruscio R, Bonardi C, et al. Pentraxin 3 in plasma and vaginal fluid in women with preterm delivery. BJOG. 2007;114(2):143–147.
  • Cruciani L, Romero R, Vaisbuch E, et al. Pentraxin 3 in maternal circulation: an association with preterm labor and preterm PROM, but not with intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med. 2010;23(10):1097–1105.
  • Chen X, Scholl TO. Maternal biomarkers of endothelial dysfunction and preterm delivery. PLoS One. 2014;9(1):e85716.
  • Tarca AL, Pataki B, Romero R, DREAM Preterm Birth Prediction Challenge Consortium, et al. Crowdsourcing assessment of maternal blood multi-omics for predicting gestational age and preterm birth. Cell Rep Med. 2021;2(6):100323.
  • Romero R, Chaiworapongsa T, Erez O, et al. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med. 2010;23(12):1384–1399.
  • Espinoza J, Chaiworapongsa T, Romero R, et al. Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med. 2007;20(7):495–507.
  • Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109(6):1316–1324.
  • Chaiworapongsa T, Romero R, Erez O, et al. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio). Am J Obstet Gynecol. 2017;217(6):682.e1–e13.
  • Erez O, Gotsch F, Mazaki-Tovi S, et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med. 2009;22(8):672–687.
  • Ay C, Kaider A, Koder S, et al. Association of elevated soluble P-selectin levels with fetal loss in women with a history of venous thromboembolism. Thromb Res. 2012;129(6):725–728.
  • Richani K, Romero R, Soto E, et al. Unexplained intrauterine fetal death is accompanied by activation of complement. J Perinat Med. 2005;33(4):296–305.
  • Rieckmann P, D'Alessandro F, Nordan RP, et al. IL-6 and tumor necrosis factor-alpha. Autocrine and paracrine cytokines involved in B cell function. J Immunol. 1991;146(10):3462–3468.
  • Cassatella MA, Meda L, Bonora S, et al. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993;178(6):2207–2211.
  • Arzt E, Stalla GK. Cytokines: autocrine and paracrine roles in the anterior pituitary. Neuroimmunomodulation. 1996;3(1):28–34.
  • Kaplan D. Autocrine secretion and the physiological concentration of cytokines. Immunol Today. 1996;17(7):303–304.
  • Renner U, Pagotto U, Arzt E, et al. Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur J Endocrinol. 1996;135(5):515–532.
  • Rothwell NJ. The endocrine significance of cytokines. J Endocrinol. 1991;128(2):171–173.
  • Vassilopoulou-Sellin R. Endocrine effects of cytokines. Oncology. 1994;8(10):43–50.
  • Silva CM, Isgaard J, Thorner MO. Cytokines in endocrine function. Adv Protein Chem. 1998;52:199–221.
  • Smárason AK, Sargent IL, Starkey PM, et al. The effect of placental syncytiotrophoblast microvillous membranes from normal and pre-eclamptic women on the growth of endothelial cells in vitro. Br J Obstet Gynaecol. 1993;100(10):943–949.
  • Cockell AP, Learmont JG, Smárason AK, et al. Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function. Br J Obstet Gynaecol. 1997;104(2):235–240.
  • Redman CW, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta. 2000;21(7):597–602.
  • Sabapatha A, Gercel-Taylor C, Taylor DD. Specific isolation of placenta-derived exosomes from the circulation of pregnant women and their immunoregulatory consequences. Am J Reprod Immunol. 2006;56(5-6):345–355.
  • Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
  • Ouyang Y, Mouillet JF, Coyne CB, et al. Review: placenta-specific microRNAs in exosomes - good things come in nano-packages. Placenta. 2014;35 Suppl: s 69–73.
  • Delorme-Axford E, Donker RB, Mouillet JF, et al. Human placental trophoblasts confer viral resistance to recipient cells. Proc Natl Acad Sci U S A. 2013;110(29):12048–12053.
  • Gardiner C, Tannetta DS, Simms CA, et al. Syncytiotrophoblast microvesicles released from pre-eclampsia placentae exhibit increased tissue factor activity. PLOS One. 2011;6(10):e26313.
  • Taylor DD, Akyol S, Gercel-Taylor C. Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol. 2006;176(3):1534–1542.
  • Zaborowski MP, Balaj L, Breakefield XO, et al. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience. 2015;65(8):783–797.
  • Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289.
  • Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, et al. Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. 2020;21(16):5840.
  • Gai C, Pomatto MAC, Grange C, et al. Extracellular vesicles in onco-nephrology. Exp Mol Med. 2019;51(3):1–8.
  • Marar C, Starich B, Wirtz D. Extracellular vesicles in immunomodulation and tumor progression. Nat Immunol. 2021;22(5):560–570.
  • Croft PK, Sharma S, Godbole N, et al. Ovarian-Cancer-Associated extracellular vesicles: microenvironmental regulation and potential clinical applications. Cells. 2021;10(9):2272.
  • van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–228.
  • Karpman D, Ståhl AL, Arvidsson I. Extracellular vesicles in renal disease. Nat Rev Nephrol. 2017;13(9):545–562.
  • Fitzgerald W, Freeman ML, Lederman MM, et al. A system of cytokines encapsulated in ExtraCellular vesicles. Sci Rep. 2018;8(1):8973.
  • Fitzgerald W, Gomez-Lopez N, Erez O, et al. Extracellular vesicles generated by placental tissues ex vivo: a transport system for immune mediators and growth factors. Am J Reprod Immunol. 2018;80(1):e12860.
  • Committee opinion no 700: methods for estimating the due date. Obstet Gynecol. 2017;129:e150–e4.
  • Macdorman MF, Kirmeyer S. The challenge of fetal mortality. NCHS Data Brief. 2009;(16):1–8.
  • Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol. 1996;87(2):163–168.
  • ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159–167.
  • Langston C, Kaplan C, Macpherson T, et al. Practice guideline for examination of the placenta: developed by the placental pathology practice guideline development task force of the College of American Pathologists. Arch Pathol Lab Med. 1997;121(5):449–476.
  • Romero R, Kim YM, Pacora P, et al. The frequency and type of placental histologic lesions in term pregnancies with normal outcome. J Perinat Med. 2018;46(6):613–630.
  • Redline RW, Heller D, Keating S, et al. Placental diagnostic criteria and clinical correlation–a workshop report. Placenta. 2005;26 (Suppl A): s 114–7.
  • Khong TY, Mooney EE, Ariel I, et al. Sampling and definitions of placental lesions: amsterdam placental workshop group consensus statement. Arch Pathol Lab Med. 2016;140(7):698–713.
  • Bhatti G, Romero R, Rice GE, et al. Compartmentalized profiling of amniotic fluid cytokines in women with preterm labor. PLoS ONE. 2020;15(1):e0227881.
  • Sass D, Fitzgerald W, Wolff BS, et al. Differences in circulating extracellular vesicle and soluble cytokines in older versus younger breast cancer patients with distinct symptom profiles. Front Genet. 2022;13:869044.
  • Uddin S, Khan A, Hossain ME, et al. Comparing different supervised machine learning algorithms for disease prediction. BMC Med Inform Decis Mak. 2019;19(1):281.
  • Díaz-Uriarte R, Alvarez de Andrés S. Gene selection and classification of microarray data using random Forest. BMC Bioinformatics. 2006;7:3.
  • Goldstein BA, Hubbard AE, Cutler A, et al. An application of random forests to a genome-wide association dataset: methodological considerations & new findings. BMC Genet. 2010;11:49.
  • Zolfaghari F, Khosravi H, Shahriyari A, et al. Hierarchical cluster analysis to identify the homogeneous desertification management units. PLOS One. 2019;14(12):e0226355.
  • Zhang Z, Murtagh F, Van Poucke S, et al. Hierarchical cluster analysis in clinical research with heterogeneous study population: highlighting its visualization with R. Ann Transl Med. 2017;5(4):75.
  • Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847–2849.
  • Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412–9420.
  • Lo Cicero A, Stahl PD, Raposo G. Extracellular vesicles shuffling intercellular messages: for good or for bad. Curr Opin Cell Biol. 2015;35:69–77.
  • Zhang J, Li H, Fan B, et al. Extracellular vesicles in normal pregnancy and pregnancy-related diseases. J Cell Mol Med. 2020;24(8):4377–4388.
  • Mitchell MD, Peiris HN, Kobayashi M, et al. Placental exosomes in normal and complicated pregnancy. Am J Obstet Gynecol. 2015;213(4 Suppl):S173–S81.
  • Buca D, D'Antonio F, Buca D, et al. Extracellular vesicles in pregnancy: their potential role as a liquid biopsy. J Reprod Immunol. 2022;154:103734.
  • Hashimoto A, Sugiura K, Hoshino A. Impact of exosome-mediated feto-maternal interactions on pregnancy maintenance and development of obstetric complications. J Biochem. 2021;169(2):163–171.
  • Mincheva-Nilsson L, Baranov V. Placenta-derived exosomes and syncytiotrophoblast microparticles and their role in human reproduction: immune modulation for pregnancy success. Am J Reprod Immunol. 2014;72(5):440–457.
  • Truong G, Guanzon D, Kinhal V, et al. Oxygen tension regulates the miRNA profile and bioactivity of exosomes released from extravillous trophoblast cells – liquid biopsies for monitoring complications of pregnancy. PLOS One. 2017;12(3):e0174514.
  • Hadley EE, Sheller-Miller S, Saade G, et al. Amnion epithelial cell-derived exosomes induce inflammatory changes in uterine cells. Am J Obstet Gynecol. 2018;219(5):e1–e21.
  • Menon R, Bonney EA, Condon J, et al. Novel concepts on pregnancy clocks and alarms: redundancy and synergy in human parturition. Hum Reprod Update. 2016;22(5):535–560.
  • Toth B, Lok CA, Böing A, et al. Microparticles and exosomes: impact on normal and complicated pregnancy. Am J Reprod Immunol. 2007;58(5):389–402.
  • Mouillet JF, Ouyang Y, Coyne CB, et al. MicroRNAs in placental health and disease. Am J Obstet Gynecol. 2015;213(4 Suppl):S163–S72.
  • Jia R, Li J, Rui C, et al. Comparative proteomic profile of the human umbilical cord blood exosomes between normal and preeclampsia pregnancies with high-resolution mass spectrometry. Cell Physiol Biochem. 2015;36(6):2299–2306.
  • Dragovic RA, Southcombe JH, Tannetta DS, et al. Multicolor flow cytometry and nanoparticle tracking analysis of extracellular vesicles in the plasma of normal pregnant and pre-eclamptic women. Biol Reprod. 2013;89(6):151.
  • Luo R, Shao X, Xu P, et al. MicroRNA-210 contributes to preeclampsia by downregulating potassium channel modulatory factor 1. Hypertension. 2014;64(4):839–845.
  • Biró O, Alasztics B, Molvarec A, et al. Various levels of circulating exosomal total-miRNA and miR-210 hypoxamiR in different forms of pregnancy hypertension. Pregnancy Hypertens. 2017;10:207–212.
  • Salomon C, Guanzon D, Scholz-Romero K, et al. Placental exosomes as early biomarker of preeclampsia: potential role of exosomal MicroRNAs across gestation. J Clin Endocrinol Metab. 2017;102(9):3182–3194.
  • Tan KH, Tan SS, Sze SK, et al. Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles. Am J Obstet Gynecol. 2014;211(4):380.e1-13–380.13.
  • Salomon C, Scholz-Romero K, Sarker S, et al. Gestational diabetes mellitus is associated with changes in the concentration and bioactivity of placenta-derived exosomes in maternal circulation across gestation. Diabetes. 2016;65(3):598–609.
  • James-Allan LB, Devaskar SU. Extracellular vesicles and their role in gestational diabetes mellitus. Placenta. 2021;113:15–22.
  • Palma C, McIntyre HD, Salomon C. Extracellular vesicles-New players in cell-to-cell communication in gestational diabetes mellitus. Biomedicines. 2022;10(2):462.
  • Ye Z, Wang S, Huang X, Chen P, Deng L, Li S, et al. Plasma exosomal microRNAs associated with metabolism as early predictor of gestational diabetes mellitus. Diabetes. 2022;71(11):2272–2283.
  • Nair S, Ormazabal V, Lappas M, et al. Extracellular vesicles and their potential role inducing changes in maternal insulin sensitivity during gestational diabetes mellitus. Am J Reprod Immunol. 2021;85(2):e13361.
  • Dixon CL, Sheller-Miller S, Saade GR, et al. Amniotic fluid exosome proteomic profile exhibits unique pathways of term and preterm labor. Endocrinology. 2018;159(5):2229–2240.
  • Menon R, Debnath C, Lai A, et al. Protein profile changes in circulating placental extracellular vesicles in term and preterm births: a longitudinal study. Endocrinology. 2020;161(4):161.
  • Cook J, Bennett PR, Kim SH, et al. First trimester circulating microRNA biomarkers predictive of subsequent preterm delivery and cervical shortening. Sci Rep. 2019;9(1):5861.
  • Fallen S, Baxter D, Wu X, et al. Extracellular vesicle RNAs reflect placenta dysfunction and are a biomarker source for preterm labour. J Cell Mol Med. 2018;22(5):2760–2773.
  • Menon R, Debnath C, Lai A, Garbhini Study Team, et al. Circulating exosomal miRNA profile during term and preterm birth pregnancies: a longitudinal study. Endocrinology. 2019;160(2):249–275.
  • Chaiworapongsa T, Kusanovic JP, Savasan ZA, et al. Fetal death: a condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments. J Matern Fetal Neonatal Med. 2010;23(9):960–972.
  • Chaiworapongsa T, Romero R, Kusanovic JP, et al. Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. J Matern Fetal Neonatal Med. 2010;23(8):794–805.
  • Whitten AE, Romero R, Korzeniewski SJ, et al. Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol. 2013;208(4):e1–e11.
  • Korzeniewski SJ, Romero R, Chaiworapongsa T, et al. Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study. Am J Obstet Gynecol. 2016;214(5):629.e1–629.e17.
  • Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649.
  • Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005.
  • Fisher SJ. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol. 2004;2(1):53.
  • Soto E, Romero R, Kusanovic JP, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med. 2012;25(5):498–507.
  • Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21:9–23.
  • Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21(5):279–287.
  • Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 2009;22(11):1021–1038.
  • Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med. 2011;24(10):1187–1207.
  • Stepan H, Geipel A, Schwarz F, et al. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol. 2008;198(2):175.e1-6–175.e6.
  • Toft JH, Lian IA, Tarca AL, et al. Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies. J Matern Fetal Neonatal Med. 2008;21(4):267–273.
  • Jaiman S, Romero R, Gotsch F, et al. Fetal sepsis: a cause of stillbirth. J Matern Fetal Neonatal Med. 2022;35(25):9966–9970.
  • McClure EM, Saleem S, Goudar SS, et al. Stillbirth 2010–2018: a prospective, population-based, multi-country study from the global network. Reprod Health. 2020;17(Suppl 2):146.
  • Fernandez HN, Hugli TE. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem. 1978;253(19):6955–6964.
  • Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004;4(2):133–142.
  • Kuzmicki M, Telejko B, Zonenberg A, et al. Circulating pro- and anti-inflammatory cytokines in polish women with gestational diabetes. Horm Metab Res. 2008;40(8):556–560.
  • Gallo DM, Romero R, Bosco M, Chaiworapongsa T, Gomez-Lopez N, Arenas-Hernandez M, et al. Maternal plasma cytokines and the subsequent risk of uterine atony and postpartum hemorrhage. J Perinat Med. 2022;
  • Brien ME, Boufaied I, Bernard N, et al. Specific inflammatory profile in each pregnancy complication: a comparative study. Am J Reprod Immunol. 2020;84(6):e13316.
  • Lumbreras-Marquez MI, Lumbreras-Marquez J, Barraza-Salas M, et al. Maternal and umbilical cord procalcitonin, high-sensitivity C-reactive protein, and interleukin-6 levels in preeclamptic and normotensive patients: a cross-sectional study. Pregnancy Hypertens. 2020;21:218–223.
  • Romero R, Chaemsaithong P, Chaiyasit N, et al. CXCL10 and IL-6: markers of two different forms of intra-amniotic inflammation in preterm labor. Am J Reprod Immunol. 2017;78(1):e12685.
  • Chaemsaithong P, Romero R, Korzeniewski SJ, et al. A point of care test for the determination of amniotic fluid interleukin-6 and the chemokine CXCL-10/IP-10. J Matern Fetal Neonatal Med. 2015;28(13):1510–1519.
  • Stranik J, Kacerovsky M, Andrys C, et al. Intra-amniotic infection and sterile intra-amniotic inflammation are associated with elevated concentrations of cervical fluid interleukin-6 in women with spontaneous preterm labor with intact membranes. J Matern Fetal Neonatal Med. 2021;35(25):4861–4869.
  • Chaemsaithong P, Romero R, Docheva N, et al. Comparison of rapid MMP-8 and interleukin-6 point-of-care tests to identify intra-amniotic inflammation/infection and impending preterm delivery in patients with preterm labor and intact membranes. J Matern Fetal Neonatal Med. 2018;31(2):228–244.
  • Chaemsaithong P, Romero R, Korzeniewski SJ, et al. A rapid interleukin-6 bedside test for the identification of intra-amniotic inflammation in preterm labor with intact membranes. J Matern Fetal Neonatal Med. 2016;29(3):349–359.
  • Yoon BH, Romero R, Kim CJ, et al. Amniotic fluid interleukin-6: a sensitive test for antenatal diagnosis of acute inflammatory lesions of preterm placenta and prediction of perinatal morbidity. Am J Obstet Gynecol. 1995;172(3):960–970.
  • Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol. 1997;177(1):19–26.
  • Kim CJ, Romero R, Chaemsaithong P, et al. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol. 2015;213(4):S29–S52.
  • Lagodka S, Petrucci S, Moretti ML, et al. Fetal and maternal inflammatory response in the setting of maternal intrapartum fever with and without clinical and histologic chorioamnionitis. Am J Obstet Gynecol MFM. 2022;4(2):100539.
  • Hammond ME, Lapointe GR, Feucht PH, et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol. 1995;155(3):1428–1433.
  • Zinkernagel AS, Timmer AM, Pence MA, et al. The IL-8 protease SpyCEP/ScpC of group a Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe. 2008;4(2):170–178.
  • Estrada-Gutierrez G, Cappello RE, Mishra N, et al. Increased expression of matrix metalloproteinase-1 in systemic vessels of preeclamptic women: a critical mediator of vascular dysfunction. Am J Pathol. 2011;178(1):451–460.
  • Zhang YJ, Rutledge BJ, Rollins BJ. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem. 1994;269(22):15918–15924.
  • Weber M, Uguccioni M, Baggiolini M, et al. Deletion of the NH2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant. J Exp Med. 1996;183(2):681–685.
  • Kameyoshi Y, Dörschner A, Mallet AI, et al. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992;176(2):587–592.
  • Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–366.
  • Bottazzi B, Garlanda C, Cotena A, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev. 2009;227(1):9–18.
  • Cetin I, Cozzi V, Pasqualini F, et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006;194(5):1347–1353.
  • Cetin I, Cozzi V, Papageorghiou AT, et al. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol Scand. 2009;88(7):846–849.
  • Galbiati S, Causarano V, Pinzani P, et al. Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. Clin Chem Lab Med. 2010;48(6):791–794.
  • Boij R, Svensson J, Nilsson-Ekdahl K, et al. Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol. 2012;68(3):258–270.
  • Colmenares-Mejía CC, Quintero-Lesmes DC, Bautista-Niño PK, et al. Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: genPE study. Hypertens Res. 2020;43(9):884–891.
  • Cruciani L, Romero R, Vaisbuch E, et al. Pentraxin 3 in amniotic fluid: a novel association with intra-amniotic infection and inflammation. J Perinat Med. 2010;38(2):161–171.
  • Cozzi V, Garlanda C, Nebuloni M, et al. PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. Placenta. 2012;33(12):1039–1044.
  • El-Azzamy H, Balogh A, Romero R, et al. Characteristic changes in decidual gene expression signature in spontaneous term parturition. J Pathol Transl Med. 2017;51(3):264–283.
  • Than NG, Romero R, Erez O, et al. Emergence of hormonal and redox regulation of galectin-1 in placental mammals: implication in maternal-fetal immune tolerance. Proc Natl Acad Sci U S A. 2008;105(41):15819–15824.
  • Than NG, Erez O, Wildman DE, et al. Severe preeclampsia is characterized by increased placental expression of galectin-1. J Matern Fetal Neonatal Med. 2008;21(7):429–442.
  • Than NG, Kim SS, Abbas A, et al. Chorioamnionitis and increased galectin-1 expression in PPROM –an anti-inflammatory response in the fetal membranes? Am J Reprod Immunol. 2008;60(4):298–311.
  • Than NG, Romero R, Kim CJ, et al. Galectins: guardians of eutherian pregnancy at the maternal-fetal interface. Trends Endocrinol Metab. 2012;23(1):23–31.
  • Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1–5.
  • Schnabel A, Blois SM, Meint P, et al. Elevated systemic galectin-1 levels characterize HELLP syndrome. J Reprod Immunol. 2016;114:38–43.
  • Jeschke U, Mayr D, Schiessl B, et al. Expression of galectin-1, -3 (gal-1, gal-3) and the Thomsen-Friedenreich (TF) antigen in normal, IUGR, preeclamptic and HELLP placentas. Placenta. 2007;28(11-12):1165–1173.
  • Broze GJ, Jr., Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71(2):335–343.
  • Wun TC, Kretzmer KK, Girard TJ, et al. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 1988;263(13):6001–6004.
  • Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989;338(6215):518–520.
  • Kaiser B, Fareed J. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb Haemost. 1996;76(04):615–620.
  • Sandset PM, Warn-Cramer BJ, Rao LV, et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A. 1991;88(3):708–712.
  • Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med. 2001;29(7 Suppl):S90–S4.
  • Mosad E, Elsayh KI, Eltayeb AA. Tissue factor pathway inhibitor and P-selectin as markers of sepsis-induced non-overt disseminated intravascular coagulopathy. Clin Appl Thromb Hemost. 2011;17(1):80–87.
  • Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb Res. 1995;80(4):339–348.
  • Shimura M, Wada H, Wakita Y, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol. 1997;55(4):169–174.
  • Asakura H, Ontachi Y, Mizutani T, et al. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis. 2001;12(1):1–8.
  • Gando S, Kameue T, Morimoto Y, et al. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med. 2002;30:1729–1734.
  • Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006;208(3):327–339.
  • Feng Q, Liu K, Liu YX, et al. Plasminogen activators and inhibitors are transcribed during early macaque implantation. Placenta. 2001;22(2–3):186–199.
  • Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol. 1999;11(5):634–640.
  • Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998;10(5):602–608.
  • Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85(10):906–911.
  • Fernandez-Patron C, Stewart KG, Zhang Y, et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res. 2000;87(8):670–676.
  • Kveiborg M, Albrechtsen R, Couchman JR, et al. Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol. 2008;40(9):1685–1702.
  • Walsh SW, Strauss JF. Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia? Am J Obstet Gynecol. 2022;226(2S):S945–S953.
  • Walsh SW, Nugent WH, Al Dulaimi M, et al. Proteases activate pregnancy neutrophils by a Protease-Activated receptor 1 pathway: epigenetic implications for preeclampsia. Reprod Sci. 2020;27(11):2115–2127.
  • Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn. 2007;27(3):264–271.
  • Laigaard J, Sørensen T, Placing S, et al. Reduction of the disintegrin and metalloprotease ADA. M12 in preeclampsia. Obstet Gynecol. 2005;106(1):144–149.
  • Karagiannis G, Akolekar R, Sarquis R, et al. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther. 2011;29(2):148–154.
  • Andres F, Wong GP, Walker SP, et al. A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeks’ gestation in pregnancies destined to deliver small for gestational age infants. Placenta. 2022;117:1–4.
  • El-Sherbiny W, Nasr A, Soliman A. Metalloprotease (ADAM12-S) as a predictor of preeclampsia: correlation with severity, maternal complications, fetal outcome, and Doppler parameters. Hypertens Pregnancy. 2012;31(4):442–450.
  • Yu N, Cui H, Chen X, et al. First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction. Taiwan J Obstet Gynecol. 2017;56(3):358–361.
  • Harmon QE, Huang L, Umbach DM, et al. Risk of fetal death with preeclampsia. Obstet Gynecol. 2015;125(3):628–635.
  • Karaszi K, Szabo S, Juhasz K, et al. Increased placental expression of placental protein 5 (PP5)/tissue factor pathway inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: relevance to impaired trophoblast invasion? Placenta. 2019;76:30–39.
  • MacDonald TM, Tong S, Myers J, et al. Circulating tissue factor pathway inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. Placenta. 2021;105:32–40.
  • Walsh SW, Nugent WH, Archer KJ, et al. Epigenetic regulation of interleukin-17-Related genes and their potential roles in neutrophil vascular infiltration in preeclampsia. Reprod Sci. 2022;29(1):154–162.
  • Laudanski P, Raba G, Kuc P, et al. Assessment of the selected biochemical markers in predicting preterm labour. J Matern Fetal Neonatal Med. 2012;25(12):2696–2699.
  • Raba G, Tabarkiewicz J. Cytokines in preterm delivery: proposal of a new diagnostic algorithm. J Immunol Res. 2018;2018:8073476.
  • Zhang S, Wang Y, Li J, et al. MiR-101 inhibits migration and invasion of trophoblast HTR-8/SVneo cells by targeting CXCL6 in preeclampsia. Minerva Med. 2021;112(2):302–303.
  • Mittal P, Romero R, Kusanovic JP, et al. CXCL6 (granulocyte chemotactic protein-2): a novel chemokine involved in the innate immune response of the amniotic cavity. Am J Reprod Immunol. 2008;60(3):246–257.
  • Mastrodima S, Akolekar R, Yerlikaya G, et al. Prediction of stillbirth from biochemical and biophysical markers at 11–13 weeks. Ultrasound Obstet Gynecol. 2016;48(5):613–617.
  • Akolekar R, Machuca M, Mendes M, et al. Prediction of stillbirth from placental growth factor at 11–13 weeks. Ultrasound Obstet Gynecol. 2016;48(5):618–623.
  • Smith GC, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87(4):1762–1767.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.